Cancer Immunotherapeutics
Cancer Immunotherapeutics - Related Videos
15:24
Testing Cancer Immunotherapeutics in a Humanized Mouse Model Bearing Human Tumors
0 Views •
Cited by 4 •
2022
This protocol outlines the generation of human immune system (HIS) mice for immuno-oncology studies. Instructions and considerations in the use of this model for testing human immunotherapeutics on human tumors implanted in this model are presented with an emphasis on characterizing the response of the human immune system to the tumor.
07:47
Studying the Role of Alveolar Macrophages in Breast Cancer Metastasis
0 Views •
Cited by 7 •
2016
Here we describe the model and approach to study functions of pulmonary alveolar macrophages in cancer metastasis. To demonstrate the role of these cells in metastasis, the syngeneic (4T1) model of breast cancer in conjunction with the depletion of alveolar macrophage with clodronate liposomes was used.
07:16
Isolation of Cancer Stem Cells From Human Prostate Cancer Samples
0 Views •
Cited by 6 •
2014
The isolation of cancer stem cells (CSCs) directly from human tissues is requisite for their biological characterization. This manuscript describes a methodology for the isolation of prostate CSCs from human tissues, while also providing tips on troubleshooting difficult steps.
08:27
Detection of Human Leukocyte Antigen Biomarkers in Breast Cancer Utilizing Label-free Biosensor Technology
0 Views •
Cited by 3 •
2015
Intact class I HLA/peptide complexes are shed by cancer cells, representing a potential relevant cancer biomarker. Utilizing label-free sensor technology and T-cell receptor mimicking monoclonal antibodies, detection of shed MIF/HLA-A*02:01 complexes in MDA-MB-231 cell supernatants, spiked human serum, and patient plasma is demonstrated, enabling development of a novel cancer diagnostic platform.
07:48
Working with Human Tissues for Translational Cancer Research
0 Views •
Cited by 4 •
2015
Translational cancer research is dependent on extraction of human tissues. Much work has gone into optimizing extraction methods for ex vivo analysis. Here, we describe tissue processing methods allowing for maximal data output from limited samples.
FAQs
Checkpoint blockade can restore immune activity by preventing inhibitory signals from suppressing antitumor responses. Rather than acting directly on tumor growth, this strategy changes the interaction between immune cells and malignant cells. Its benefit is therefore influenced by tumor biology and the patient’s immune status, which help explain why responses vary among individuals.
Monoclonal antibodies can mark cancer cells for immune recognition, directing immune activity toward cells carrying the relevant target. This approach differs from simply blocking an inhibitory signal because the antibody provides a more targeted connection between the malignant cell and the immune response. Its usefulness depends on whether the cancer presents a suitable target.
Tumor-associated antigens provide recognition targets for engineered immune cells. By directing these cells toward such markers, researchers aim to improve discrimination between malignant cells and other tissues. The strategy depends on the biology of the tumor and the presence of an antigen that can guide recognition, making antigen selection an important part of treatment development.
Biomarker-based patient selection helps match a treatment approach with biological features that may influence immune responsiveness. Because effectiveness depends on tumor biology and immune status, these markers can support more informed identification of patients likely to benefit. This research direction also helps clarify why a therapy may produce durable responses in some patients but not others.
Combination therapies are being investigated to address the multiple biological barriers that can limit immune-mediated tumor control. Pairing approaches may offer a way to improve recognition, counter inhibitory influences, or strengthen immune activity, although the balance between benefit and treatment-related toxicity remains important. Research continues to determine which combinations are most useful for particular tumor settings.
Evaluation must consider both response durability and treatment-related toxicity. Some patients can experience durable responses, while others show limited benefit because of tumor biology, immune status, or immune resistance. These differences make outcome interpretation more complex than measuring tumor control alone and motivate research into biomarkers, combination strategies, and methods for overcoming resistance.